The company said, “Natera is revising its 2023 annual guidance. The Company now expects annual revenue to be in a range of $1.035 billion to $1.05 billion, up from its previous range of $1.015 billion to $1.035 billion; and gross margin to be in a range of approximately 43% to 44% of revenues, revised from its previous range of 41% to 44%. The Company continues to expect selling, general and administrative costs to be approximately $540 million to $580 million, and research and development costs to be approximately $325 million to $345 million. In addition, net cash consumption is now expected to be approximately $260 million to $280 million, down from its previous range of $300 million to $325 million.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- NTRA Earnings this Week: How Will it Perform?
- Charles River price target lowered to $220 from $235 at Morgan Stanley
- Natera announced updated data from GALAXY arm of CIRCULATE-Japan trial
- Natera price target lowered to $70 from $80 at Piper Sandler
- DermTech, Natera can benefit from California biomarker law, says Craig-Hallum